The Estimated Lifetime Medical Cost of Syphilis in the United States
- PMID: 33492088
- PMCID: PMC10028531
- DOI: 10.1097/OLQ.0000000000001353
The Estimated Lifetime Medical Cost of Syphilis in the United States
Abstract
Background: The purpose of this study was to estimate the cost of syphilis in the United States, in terms of the average lifetime direct medical cost per infection.
Methods: We used a decision tree model of the natural history of syphilis. The model allowed for numerous possible outcomes of infection, including treatment for syphilis at various stages, inadvertent treatment, and late syphilis outcomes in those who are alive and still infected 30 years after acquisition. Future costs were discounted at 3% annually. Model inputs, such as the cost and probability of each outcome, were based on published sources. The probabilities we applied yielded outcomes consistent with reported cases of syphilis by stage from national surveillance data and number of deaths due to late syphilis from national mortality data.
Results: The estimated, discounted lifetime cost per infection was $1190 under base case assumptions (2019 dollars). Treatment costs associated with late syphilis outcomes, such as cardiovascular syphilis, accounted for only $26 of the average lifetime cost per infection. Results were most sensitive to assumptions regarding the treatment cost per case of unknown duration or late syphilis. In the probabilistic sensitivity analyses, the 2.5th and 97.5th percentiles of the 10,000 simulations of the lifetime cost per infection were $729 and $1884, respectively.
Conclusions: Our estimate of the lifetime cost per infection is about 50% higher than in a previous study, a difference due in large part to our higher cost assumptions for benzathine penicillin G.
Copyright © 2021 American Sexually Transmitted Diseases Association. All rights reserved.
Conflict of interest statement
Conflict of Interest and Sources of Funding: None declared.
Figures



Similar articles
-
The Estimated Direct Lifetime Medical Costs of Sexually Transmitted Infections Acquired in the United States in 2018.Sex Transm Dis. 2021 Apr 1;48(4):215-221. doi: 10.1097/OLQ.0000000000001380. Sex Transm Dis. 2021. PMID: 33492093 Free PMC article.
-
Antenatal syphilis screening using point-of-care testing in Sub-Saharan African countries: a cost-effectiveness analysis.PLoS Med. 2013 Nov;10(11):e1001545. doi: 10.1371/journal.pmed.1001545. Epub 2013 Nov 5. PLoS Med. 2013. PMID: 24223524 Free PMC article.
-
Estimation of the Lifetime Quality-Adjusted Life Years (QALYs) Lost Due to Syphilis Acquired in the United States in 2018.Clin Infect Dis. 2023 Feb 8;76(3):e810-e819. doi: 10.1093/cid/ciac427. Clin Infect Dis. 2023. PMID: 35684943 Free PMC article.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?Clin Orthop Relat Res. 2020 Dec;478(12):2869-2888. doi: 10.1097/CORR.0000000000001416. Clin Orthop Relat Res. 2020. PMID: 32694315 Free PMC article.
Cited by
-
Access to Benzathine Penicillin G Treatment for Persons With Syphilis, Maricopa County, Arizona, 2021.Sex Transm Dis. 2024 Mar 1;51(3):192-198. doi: 10.1097/OLQ.0000000000001921. Epub 2024 Jan 3. Sex Transm Dis. 2024. PMID: 38412466 Free PMC article.
-
The Estimated Direct Lifetime Medical Costs of Sexually Transmitted Infections Acquired in the United States in 2018.Sex Transm Dis. 2021 Apr 1;48(4):215-221. doi: 10.1097/OLQ.0000000000001380. Sex Transm Dis. 2021. PMID: 33492093 Free PMC article.
-
The Impacts and Consequences of Sexually Transmitted Infections in the United States.Sex Transm Dis. 2025 May 1;52(5):285-289. doi: 10.1097/OLQ.0000000000002126. Epub 2024 Dec 23. Sex Transm Dis. 2025. PMID: 39714030 Review.
-
An Interactive Modeling Tool for Projecting the Health and Direct Medical Cost Impact of Changes in the Sexually Transmitted Diseases Prevention Program Budgets.J Public Health Manag Pract. 2024 Mar-Apr 01;30(2):221-230. doi: 10.1097/PHH.0000000000001868. J Public Health Manag Pract. 2024. PMID: 38271104 Free PMC article.
-
Short-term Impact of Changes in Public Health Information Systems on Sexually Transmitted Infection Surveillance Data Quality.Sex Transm Dis. 2025 May 23:10.1097/OLQ.0000000000002180. doi: 10.1097/OLQ.0000000000002180. Online ahead of print. Sex Transm Dis. 2025. PMID: 40407210
References
-
- Owusu-Edusei K Jr., Chesson HW, Gift TL, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 2013;40(3):197–201. - PubMed
-
- Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004;36(1):11–19. - PubMed
-
- American Social Health Association. Sexually transmitted diseases in America: How many cases and at what cost? Menlo Park, CA: Kaiser Family Foundation;1998.
-
- Chesson HW, Rein D, Kassler WJ, et al. Direct medical costs of syphilis in the United States: The potential for a cost-saving national elimination program Poster presentation. 1998 National STD Prevention Conference; Dallas, December 6–9, 1998.
-
- Schmid GP, Zaidi A. Serologic screening for syphilis: a decision model Eleventh Meeting of the International Society for STD Research; New Orleans, August 27–30, 1995.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical